Adam M Huber

Summary

Affiliation: Dalhousie University
Country: Canada

Publications

  1. pmc Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference
    Adam M Huber
    IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Care Res (Hoboken) 64:546-53. 2012
  2. pmc Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference
    Adam M Huber
    IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Care Res (Hoboken) 62:219-25. 2010
  3. pmc A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]
    Adam M Huber
    IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    BMC Med 2:7. 2004
  4. doi request reprint Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis
    Adam M Huber
    Division of Pediatric Rheumatology, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Rheum 59:214-21. 2008
  5. pmc Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats
    Adam M Huber
    Izaak Walton Killam Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Rheum 59:352-6. 2008
  6. ncbi request reprint Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies
    Adam M Huber
    IWK Health Centre and Dalhousie University, 5850 University Avenue, Halifax, Nova Scotia B3J 3G9, Canada
    Arthritis Rheum 50:1595-603. 2004
  7. doi request reprint Update on the assessment of children with juvenile idiopathic inflammatory myopathy
    Adam M Huber
    IWK Health Centre, 5850 University Avenue, Halifax, Nova Scotia, B3K 6R8, Canada
    Curr Rheumatol Rep 12:204-12. 2010
  8. doi request reprint Idiopathic inflammatory myopathies in childhood: current concepts
    Adam M Huber
    Division of Pediatric Rheumatology, IWK Health Centre, 5850 University Avenue, Halifax, NS B3K 6R8, Canada
    Pediatr Clin North Am 59:365-80. 2012
  9. ncbi request reprint Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials
    Adam M Huber
    Division of Pediatric Rheumatology, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    J Rheumatol 34:1125-32. 2007
  10. ncbi request reprint Corticosteroid treatment of refractory Kawasaki disease
    Bianca A Lang
    Canadian Pediatric Rheumatology Association, Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada
    J Rheumatol 33:803-9. 2006

Detail Information

Publications12

  1. pmc Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference
    Adam M Huber
    IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Care Res (Hoboken) 64:546-53. 2012
    ....
  2. pmc Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference
    Adam M Huber
    IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Care Res (Hoboken) 62:219-25. 2010
    ..To use juvenile dermatomyositis (DM) survey data and expert opinion to develop a small number of consensus treatment protocols, which reflect current initial treatment of moderately severe juvenile DM...
  3. pmc A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]
    Adam M Huber
    IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    BMC Med 2:7. 2004
    ..The goal of this study was to investigate whether early corticosteroid administration could reduce the rate of renal or gastrointestinal complications in children with HSP...
  4. doi request reprint Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis
    Adam M Huber
    Division of Pediatric Rheumatology, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Rheum 59:214-21. 2008
    ..To provide preliminary validation of the Cutaneous Assessment Tool (CAT), a new tool to assess cutaneous manifestations of juvenile dermatomyositis (DM), and to explore the clinical meaning of CAT scores...
  5. pmc Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats
    Adam M Huber
    Izaak Walton Killam Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Rheum 59:352-6. 2008
    ..The goal of this study was to determine whether alternative scoring methods would shorten the CAT without compromising its measurement characteristics...
  6. ncbi request reprint Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies
    Adam M Huber
    IWK Health Centre and Dalhousie University, 5850 University Avenue, Halifax, Nova Scotia B3J 3G9, Canada
    Arthritis Rheum 50:1595-603. 2004
    ....
  7. doi request reprint Update on the assessment of children with juvenile idiopathic inflammatory myopathy
    Adam M Huber
    IWK Health Centre, 5850 University Avenue, Halifax, Nova Scotia, B3K 6R8, Canada
    Curr Rheumatol Rep 12:204-12. 2010
    ..Future work will refine these assessments and definitions and--where there are multiple choices--determine which tools constitute an optimal assessment...
  8. doi request reprint Idiopathic inflammatory myopathies in childhood: current concepts
    Adam M Huber
    Division of Pediatric Rheumatology, IWK Health Centre, 5850 University Avenue, Halifax, NS B3K 6R8, Canada
    Pediatr Clin North Am 59:365-80. 2012
    ..The importance of early recognition and specialist involvement is emphasized...
  9. ncbi request reprint Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials
    Adam M Huber
    Division of Pediatric Rheumatology, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    J Rheumatol 34:1125-32. 2007
    ..intervention? (2) Compared to placebo, how likely is it that low-dose amitriptyline therapy in children aged 10-18 years with active polyarticular-course juvenile idiopathic arthritis (JIA) results in a significant improvement in pain?..
  10. ncbi request reprint Corticosteroid treatment of refractory Kawasaki disease
    Bianca A Lang
    Canadian Pediatric Rheumatology Association, Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada
    J Rheumatol 33:803-9. 2006
    ..To review the indications for corticosteroids in patients with Kawasaki disease (KD) treated by pediatric rheumatologists in Canada and to determine their efficacy on fever in patients with refractory KD...
  11. doi request reprint Coexpression of chemokine receptors CCR5, CXCR3, and CCR4 and ligands for P- and E-selectin on T lymphocytes of patients with juvenile idiopathic arthritis
    Andrew C Issekutz
    Dalhousie University, Halifax, Nova Scotia, Canada
    Arthritis Rheum 63:3467-76. 2011
    ..To investigate P- and E-selectin ligand coexpression with chemokine receptors (CKRs) on T cells in the synovial fluid (SF) and blood of children with juvenile idiopathic arthritis (JIA)...
  12. doi request reprint Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment
    Adam M Huber
    IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada
    Paediatr Drugs 11:361-74. 2009
    ..Newer therapies, such as anti-tumor necrosis factor agents and rituximab are currently being evaluated; it is not clear what role these medications will have in the future...